Scalp paradoxical psoriasis during treatment with secukinumab
DOI:
https://doi.org/10.47196/hpc17e61Keywords:
paradoxical psoriasiform reactions, scalp, psoriasis, hidradenitis suppurativa, adalimumab, secukinumabAbstract
Paradoxical psoriasiform reactions include new cases or worsening of psoriasis, during treatment with biologic agents. Anti TNF-α drugs, including adalimumab, are the most common triggers for these reactions. The disruption of the balance between TNF-α and interferon-α would be key in its etiopathogenesis. However, involvement of the IL-23/IL-17 axis has also been observed, and other agents, such as secukinumab, have been implicated in the development of these reactions. We report the case of a patient with hidradenitis suppurativa receiving secukinumab who developed a paradoxical psoriasiform reaction on the scalp.
References
I. Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol. 2018;53:49-63.
II. Sociedad Argentina de Dermatología. Grupo de Psoriasis. Consenso nacional de psoriasis. Guía de tratamiento. Actualización 2024 [Internet]. Buenos Aires: Sociedad Argentina de Dermatología; 2024 [citado 2025 Mar 20]. Disponible en: https://sad.org.ar/wp-content/uploads/2024/08/CONSENSO-NACIONAL-PSORIASIS-2024.pdf.
III. Camela E, Potestio L, Fabbrocini G, Megna M. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther. 2022;22:1435-1437.
IV. Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: A review of the literature. Actas Dermosifiliogr. 2018;109:791-800.
V. Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022;10:1485.
VI. Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, et al. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Eur J Dermatol. 2021;31:307-317.
VII. Wang Y, Yang F, Wang R, Luo S. Paradoxical psoriasis induced by IL-17 antagonists. Indian J Dermatol Venereol Leprol. 2024;90:623-631.
VIII. Rodríguez IS, Castillo-Gutiérrez M, Pinedo-Moraleda F, Aranegui-Arteaga B. Paradoxical psoriasiform alopecia secondary to secukinumab: a case report. An Bras Dermatol. 2025;100:501155.
IX. Chaitidis N, Papadopoulou Z, Varvara ST, Panagiotidis M, et al. Paradoxical psoriasis induced by IL-17 inhibitors: A case series of patients with axial spondyloarthritis and a systematic literature review. Rheumatol Int. 2024;44:2659-2668.
X. Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86:1080-1091.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
